Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study

NCT04405375 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT04405375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04405375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 21, 2020
Completion date
April 30, 2023
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk/t-cell lymphoma, nasal type